What is the STEADFAST Study?The STEADFAST Study is a clinical trial, or research study, that will evaluate a new investigational medication, azeliragon (TTP488), as an addition to many of the commonly prescribed medications for patients with mild-stage Alzheimer’s disease. Azeliragon works by blocking a receptor in the brain that binds to substances such as amyloid beta, a protein thought to contribute to the symptoms of Alzheimer’s disease.
• There will be two groups of people in the study:
• One group will receive azeliragon (5 mg daily taken orally) in addition to their regular medication(s).
• One group will receive a placebo (a substance with no active ingredients) in addition to their regular medication(s).
Do I qualify for this study?You may quality for this study if you:
• Have been diagnosed with mild Alzheimer’s disease.
• Are at least 50 years of age.
• Have been taking one or more of the following medications for at least 3 months: memantine (Namenda® or Ebixa®), galantamine (Razadyne® or Reminyl®), Aricept® or Exelon®.
What will I need to do for the STEADFAST Study?
• The study will last approximately 23 months and involves about 9 visits to the doctor’s office, with most visits occurring every 3 months.
• You must attend all study visits with your caregiver.
• You will need to take your study medication every day, as instructed.
• You must continue to take your regular Alzheimer’s disease medication as you normally do.
• You will need to tell the study doctor of any changes to your health or medications while in the study.
Why should I consider participating in the STEADFAST Study?
• By participating in this study, you can learn more about the treatment of Alzheimer’s disease.
• You may receive the study medication, azeliragon, which may be effective at slowing the progression of Alzheimer’s disease
• Participating in studies helps advance research, which may help the future treatment of this currently incurable disease.